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ABSTRACT
Aims/Introduction: To provide age- and sex-specific trends, age-standardized trends,
and projections of diabetes prevalence through the year 2030 in the Japanese adult pop-
ulation.
Materials and Methods: In the present meta-regression analysis, we included 161,087
adults from six studies and nine national health surveys carried out between 1988 and
2011 in Japan. We assessed the prevalence of diabetes using a recorded history of diabe-
tes or, for the population of individuals without known diabetes, either a glycated hemo-
globin level of ≥6.5% (48 mmol/mol) or the 1999 World Health Organization criteria (i.e., a
fasting plasma glucose level of ≥126 mg/dL and/or 2-h glucose level of ≥200 mg/dL in
the 75-g oral glucose tolerance test).
Results: For both sexes, prevalence appeared to remain unchanged over the years in
all age categories except for men aged 70 years or older, in whom a significant increase
in prevalence with time was observed. Age-standardized diabetes prevalence estimates
based on the Japanese population of the corresponding year showed marked increasing
trends: diabetes prevalence was 6.1% among women (95% confidence interval [CI]
5.5–6.7), 9.9% (95% CI 9.2–10.6) among men, and 7.9% (95% CI 7.5–8.4) among the total
population in 2010, and was expected to rise by 2030 to 6.7% (95% CI 5.2–9.2), 13.1%
(95% CI 10.9–16.7) and 9.8% (95% CI 8.5–12.0), respectively. In contrast, the age-standard-
ized diabetes prevalence using a fixed population appeared to remain unchanged.
Conclusions: This large-scale meta-regression analysis shows that a substantial increase
in diabetes prevalence is expected in Japan during the next few decades, mainly as a
result of the aging of the adult population.
INTRODUCTION
Japan’s aging rate is currently the highest in the world1. Popu-
lation aging is a major public health concern globally because
of the substantial burden that aging-associated diseases place on
society. Diabetes mellitus is one of the most common aging-
associated diseases affecting the adult population worldwide. Its
repercussions on health are numerous: macrovascular and
microvascular complications, liver disease, cognitive decline,
increased susceptibility to infection, reduced life expectancy, as
well as impaired quality of life, among others2. A growing body
of evidence suggests that diabetes might also be associated with
the development of various types of cancer3–5. Furthermore, a
recent report from the International Diabetes Federation shows
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that approximately 4.5 million deaths in 2011 could be attrib-
uted to diabetes, representing more than 8% of global all-cause
mortality6. Type 2 diabetes, which accounts for most cases of
diabetes, is highly dependent on modiﬁable risk factors, such as
unhealthy eating habits, obesity and lack of physical activity. A
large proportion of diabetes cases are therefore considered pre-
ventable, and controlled trials have conﬁrmed this in Japan and
elsewhere7–9.
The availability of trends data in diabetes prevalence is thus
critical to helping policy makers and healthcare providers both
measure the extent of the problem and implement appropriate
measures to halt its spread10. Although global estimates are
valuable in alerting the international community to the ongoing
diabetes epidemic, they might fail to provide accurate informa-
tion at the speciﬁc country level. Indeed, estimates of the preva-
lence of diabetes in the Japanese population in recent
international studies differ quite substantially11–14. This discrep-
ancy could be partly attributed to the diversity of methods and
data used to produce them. In 2009, an International Expert
Committee recommended the use of glycated hemoglobin
(HbA1c) with a threshold of ≥6.5% (48 mmol/mol) to diagnose
diabetes15. The American Diabetes Association, World Health
Organization and Japan Diabetes Society (JDS) used this crite-
rion in 2010, 2011 and 2010, respectively16–18. Nevertheless, rel-
atively few studies have reported estimates of diabetes
prevalence using this new criterion at a national level19,20.
In the present study, we aimed to estimate age- and sex-spe-
ciﬁc trends, and projections of diabetes prevalence through the
year 2030 using the most recently adopted diagnostic criteria,
and to examine the impact of population aging on trends in
diabetes prevalence in Japan, the most rapidly aging society in
the world. To accomplish these objectives, we carried out a
meta-regression analysis of the results of studies conducted dur-
ing the past two decades in Japan.
METHODS
Criteria for the Deﬁnition of Diabetes
To estimate the frequency of diabetes, the JDS recommends the
use of either HbA1c of ≥6.5%21 (48 mmol/mol22) or 2-h
plasma glucose of ≥200 mg/dL in a 75-g oral glucose tolerance
test (OGTT)18. The use of either of these is particularly impor-
tant in the Japanese population, because screening for a fasting
plasma glucose (FPG) level of ≥126 mg/dL alone could miss a
substantial proportion of previously undiagnosed cases of diabe-
tes23. We therefore included studies that used any of the follow-
ing standard diagnostic criteria: (i) HbA1c level of ≥6.5%
(48 mmol/mol); or (ii) the 1999 World Health Organization
criteria (i.e., FPG level of ≥126 mg/dL and/or OGTT 2-h glu-
cose level of ≥200 mg/dL)24. Consistent with the JDS recom-
mendations18, studies that reported a FPG level ≥126 mg/dL,
casual glucose level, or self-report of diabetes diagnosis or treat-
ment were also included, provided they also reported the stan-
dard HbA1c or 2-h glucose diagnostic criterion. HbA1c values
are presented as percentage units, in accordance with the
National Glycohemoglobin Standardization Program, and in
mmol/mol, as recommended by the International Federation of
Clinical Chemistry and Laboratory Medicine22.
Study Population and Data Collection
We searched the MEDLINE, EMBASE and Ichushi (Japana
Centra Revuo Medicina) databases through March 201325. Two
investigators (AG and MG) selected studies that were carried
out in the Japanese population, and that evaluated the preva-
lence of diabetes using either of the aforementioned diagnostic
criteria. The MEDLINE search terms were ‘Prevalence’ (MeSH
terms) AND (‘diabetes mellitus’ [MeSH:noExp] OR ‘diabetes
mellitus, type 20[MeSH terms]) AND (‘Japan’ [MeSH terms]
OR ‘Japan’ [all ﬁelds]). Similar search terms were used to
search the EMBASE and Ichushi databases. The search was lim-
ited to studies on adult human subjects with no restriction on
language. A manual search was also carried out to identify per-
tinent data sources from the references of the identiﬁed studies.
When data necessary for estimating sex- and age-speciﬁc (10-
year groups) diabetes prevalence estimates were missing,
authors were contacted and asked if they could provide the
missing information.
Initially, we identiﬁed 613 relevant articles. On the basis of
the titles and abstracts, 51 articles were considered potentially
eligible, and the entire texts of these 51 articles were reviewed.
We excluded 20 studies that did not use the standard diagnos-
tic criteria, nine duplicate studies, seven studies that did not
report diabetes prevalence and ﬁve reviews, editorials or letters
to the editor. We further excluded four studies in which sex-
and age-speciﬁc diabetes prevalence was not available26–29. SX
(investigator) of the Diabetes Epidemiology: Collaborative
analysis of Diagnostic criteria in Asia study30 coordinated by
TN, QQ and JT provided information from three studies (Hi-
sayama Study31, Funagata Study32 and Ojika Study33). One arti-
cle34 provided prevalence estimates for a subset of the study
population of the Japan Public Health Center-based Prospective
Study Diabetes Study (JPHC Diabetes Study)35; MN and ST
(investigators) of the JPHC Diabetes Study provided informa-
tion on the total population for the present study. YH, YA and
HS (investigators) of the Toranomon Hospital Health Manage-
ment Center Study36, and Machiko Inoue (investigator) of the
Yuport Medical Checkup Center Study provided information
for the present study37. One article38 provided results from the
National Survey on Circulatory Disorders in 199039. Further-
more, we retrieved an additional eight national health sur-
veys20,40–46. The study identiﬁcation process is summarized in
Figure S1 of the supplementary material.
For each selected study, we extracted the year of publication,
year(s) when data were collected, central year of data collection,
deﬁnition of diabetes, and the total number of participants and
cases of diabetes by 10-year age group and sex. The central
year was estimated as the mean between the starting and end-
ing years of data collection. This sometimes resulted in non-
integer years, but this did not constitute a problem, as year was
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considered a continuous variable in the meta-regression
analysis.
Statistical Analysis
In the ﬁrst step, the sex- and 10-year age-speciﬁc diabetes prev-
alence was estimated by meta-analysis. Prevalence estimates
from each study were transformed on the logistic link function
(or logit) scale and the corresponding variances were obtained
by the Delta method47. A random effect meta-analysis was then
carried out48. The impact of heterogeneity was measured by
means of the I2 statistic, which describes the proportion of total
variation in estimates that is as a result of heterogeneity
between studies49. In the second step, trends in diabetes preva-
lence were assessed through linear random effect meta-regres-
sion50 of the transformed prevalence estimates using year of
assessment as the independent variable. Predicted prevalence
estimates for a particular year were obtained on the logit scale
by using the estimated parameters of the linear regression
model and then transforming back to the prevalence scale using
the inverse logistic link (or expit) function. Corresponding vari-
ance estimates were computed from the covariance matrix of
the model using the Delta method. A sensitivity analysis was
carried out by repeating the meta-analysis and meta-regression
steps with the exclusion of: (i) studies using both HbA1c and
OGTT for diabetes diagnosis; and (ii) studies carried out in a
single center.
Sex-speciﬁc age-standardized estimates of the prevalence of
diabetes in the adult Japanese population (age 20 years or
older) for a given year were obtained using the direct standardi-
zation method. We estimated the age-standardized estimates
using the Japanese population distribution of the corresponding
year, year 201051,52 and year 203053, and the world population
distribution of the corresponding year, year 2010 and year
203054 as standardization populations. We computed the sum
of the 10-year age-speciﬁc prevalence estimates weighted by the
proportion of the population in the corresponding age category.
Conﬁdence intervals of the predicted age-standardized preva-
lence estimates were obtained by simulation. More precisely, we
constructed an empirical diabetes prevalence distribution for
each year of interest by sampling 20,000 times from the distri-
bution of the model parameters and calculating the correspond-
ing age-standardized prevalence estimates. Conﬁdence intervals
were then obtained by taking the 2.5 and 97.5 percentiles of
the resulting empirical diabetes prevalence distribution. The
estimated number of cases of diabetes was obtained by multi-
plying the age-standardized prevalence values by the adult Japa-
nese population estimates.
Projections of the sex- and age-speciﬁc prevalence of diabetes
until 2030 were calculated using population distribution projec-
tions53,54 under the assumption that the trends in prevalence
identiﬁed in the meta-regression would remain the same in the
next decades. The aforementioned procedure was used to com-
pute projected sex-speciﬁc age-standardized diabetes prevalence
as well as the corresponding conﬁdence intervals. It should be
noted that these conﬁdence intervals do not take into account
the uncertainty in projected population estimates.
All analyses were carried out with R statistical software ver-
sion 2.15.0 (R Foundation for Statistical Computing, Vienna,
Austria)55.
RESULTS
In the present analysis, we included a total of six studies and
nine national health surveys providing diabetes prevalence esti-
mates for 161,087 individuals (75,250 men and 85,837 women)
from 1988 to 2011. Four studies were population-based31–33,35,
two were carried out at single centers36,37 and nine were
national health surveys20,39–46. Three studies deﬁned diabetes
using OGTT31–33, whereas 12 used HbA1c20,35–37,39–46. Ignoring
the effect of age and year of assessment, the overall observed
prevalence was 11.5% (8,681 cases) for men and 6.9% (5,925
cases) for women. Details of the studies’ characteristics are
summarized in Table 1.
Age- and sex-speciﬁc estimates showed that the prevalence
of diabetes increased with age for both sexes and was higher
among men than women in all age categories between 1990
and 2010 (Table 2, Figure S2–S3). For both sexes, the preva-
lence of diabetes appeared to remain unchanged over the years
in all age categories, except for men aged 70 years or older, in
whom a signiﬁcantly increasing trend in diabetes prevalence
over time was observed (Tables 2 and S1). Trends in the age-
standardized prevalence using the Japanese population of the
corresponding year as a standardization population showed an
increase among both sexes, which was slightly greater among
men (22%) than women (14%), from 1990 to 2010. Diabetes
prevalence was 8.1% among men, 5.3% among women and
6.6% among the total population in 1990, and rose to 9.9, 6.1
and 7.9% in 2010, respectively (Table 3). In contrast, the age-
standardized prevalence using a ﬁxed population (2010 Japa-
nese, 2010 world, 2030 Japanese or 2030 world population)
appeared to remain unchanged over the years, suggesting that
population aging is the main factor inﬂuencing trends in diabe-
tes prevalence in the Japanese adult population. The age-stan-
dardized diabetes prevalence using the 2010 Japanese
population as a standardization population was 9.3% among
men, 6.6% among women and 7.9% among the total popula-
tion in 1990, and 9.9, 6.1 and 7.9% in 2010, respectively
(Table 3).
Projected age- and sex-speciﬁc estimates showed that the
prevalence of diabetes might increase with age among men and
women, and should be higher among men than women in all
age categories between 2015 and 2030 (Table 4). In both sexes,
there appeared to be slight decreasing trends in the projected
age- and sex-speciﬁc diabetes prevalence for individuals in the
ﬁrst four younger age categories (Table 4); however, these
decreasing trends were not statistically signiﬁcant (Table S1).
For men aged 70 years or older, it is projected that there
should be a signiﬁcant increasing trend in diabetes prevalence
with time (Table 4, Table S1). A further increase in the age-
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standardized prevalence using the Japanese population of the
corresponding year is projected during 2010 to 2030, if the
trend observed remains similar, namely an increase of 33% for
men and 10% for women (Table 5). In women, it is probable
that this trend is mainly a result of the aging of the population,
because age-speciﬁc prevalence estimates remained constant:
the proportion of women aged 70 years or older is expected to
increase from 23% in 2010 to 33% in 2030, whereas the pro-
portion of women aged less than 40 years is expected to
decrease from 29% in 2010 to 22% in 2030. For men, it
appears that the increasing trend in diabetes prevalence is a
result of the combined effect of the aging of the population
(17% of men aged 70 or older in 2010 vs 26% in 2030) and
the increase in the age-speciﬁc diabetes prevalence in the older
age categories. The overall prevalence of diabetes in the Japa-
nese adult population is expected to rise from 7.9% (represent-
ing about 8.3 million people with diabetes) in 2010 to 9.8%
(9.7 million people with diabetes) in 2030. In contrast, the pro-
jected age-standardized diabetes prevalence using a ﬁxed popu-
lation (2010 Japanese, 2010 world, 2030 Japanese or 2030
world population) as a standardization population appeared to
remain stable between 2015 and 2030 (Table 5).
Table 2 | Estimated age- and sex-specific diabetes prevalence (%) in the Japanese population 1990–2010
Sex Year Age category (years)
20–29 30–39 40–49 50–59 60–69 ≥70
Men 1990 0.99 (0.15–6.23) 2.87 (1.98–4.14) 7.71 (6.19–9.57) 14.17 (11.84–16.87) 14.62 (12.46–17.09) 14.52 (12.11–17.31)
1995 0.93 (0.27–3.15) 2.52 (1.97–3.23) 7.11 (6.08–8.30) 13.60 (12.00–15.37) 15.37 (13.77–17.13) 15.79 (13.94–17.84)
2000 0.87 (0.44–1.71) 2.21 (1.89–2.60) 6.55 (5.77–7.42) 13.05 (11.90–14.29) 16.15 (14.93–17.45) 17.15 (15.74–18.63)
2005 0.81 (0.46–1.45) 1.94 (1.63–2.32) 6.04 (5.18–7.01) 12.51 (11.27–13.88) 16.96 (15.59–18.42) 18.59 (17.10–20.19)
2010 0.76 (0.26–2.17) 1.71 (1.29–2.26) 5.56 (4.48–6.87) 12.00 (10.29–13.95) 17.81 (15.79–20.03) 20.13 (17.87–22.60)
Women 1990 0.79 (0.18–3.43) 1.45 (0.63–3.29) 3.51 (2.17–5.62) 7.05 (5.40–9.18) 10.25 (8.14–12.86) 12.30 (10.10–14.91)
1995 0.74 (0.27–1.98) 1.24 (0.69–2.24) 3.19 (2.26–4.49) 6.64 (5.50–8.01) 10.35 (8.79–12.14) 12.26 (10.67–14.04)
2000 0.69 (0.37–1.26) 1.06 (0.69–1.63) 2.91 (2.20–3.82) 6.26 (5.43–7.20) 10.45 (9.27–11.77) 12.21 (11.07–13.45)
2005 0.64 (0.37–1.11) 0.91 (0.59–1.40) 2.64 (1.92–3.62) 5.90 (5.02–6.92) 10.55 (9.26–12.04) 12.17 (10.98–13.46)
2010 0.59 (0.24–1.46) 0.78 (0.43–1.41) 2.40 (1.55–3.72) 5.56 (4.41–6.98) 10.65 (8.84–12.79) 12.12 (10.46–14.00)
Data are point estimates (95% confidence intervals) of prevalence.
Table 3 | Estimated age-standardized diabetes prevalence in the Japanese population 1990–2010
Sex Year Standardization population
Japanese population of the
corresponding year
World population of
the corresponding year
2010 Japanese
population
2010 world
population
2030 Japanese
population
2030 world
population
No. cases
(91,000)
Men 1990 8.06 (7.38–9.31) 3,546 6.25 (5.65–7.96) 9.30 (8.57–10.43) 6.84 (6.22–8.36) 10.32 (9.46–11.50) 7.78 (7.13–9.09)
1995 8.22 (7.73–8.90) 3,858 6.16 (5.75–6.93) 9.39 (8.85–10.06) 6.69 (6.26–7.42) 10.52 (9.89–11.28) 7.71 (7.25–8.38)
2000 8.65 (8.29–9.08) 4,222 6.19 (5.90–6.56) 9.51 (9.11–9.95) 6.57 (6.27–6.95) 10.76 (10.29–11.29) 7.66 (7.33–8.05)
2005 9.21 (8.79–9.67) 4,599 6.31 (6.00–6.68) 9.67 (9.23–10.15) 6.49 (6.17–6.87) 11.05 (10.53–11.61) 7.65 (7.29–8.05)
2010 9.86 (9.24–10.60) 4,988 6.43 (5.99–7.04) 9.86 (9.24–10.60) 6.43 (5.99–7.04) 11.38 (10.63–12.24) 7.67 (7.17–8.30)
Women 1990 5.31 (4.72–6.26) 2,498 4.05 (3.55–5.09) 6.57 (5.86–7.56) 4.32 (3.80-5.32) 7.53 (6.68–8.65) 5.08 (4.51–6.04)
1995 5.40 (4.96–5.97) 2,701 3.89 (3.54–4.45) 6.42 (5.91–7.06) 4.15 (3.78–4.70) 7.39 (6.78–8.13) 4.92 (4.51–5.47)
2000 5.59 (5.25–5.98) 2,913 3.80 (3.55–4.14) 6.29 (5.91–6.73) 3.99 (3.72–4.33) 7.27 (6.82–7.77) 4.76 (4.47–5.13)
2005 5.81 (5.44–6.24) 3,116 3.75 (3.48–4.08) 6.17 (5.77–6.63) 3.84 (3.57–4.19) 7.15 (6.68–7.69) 4.62 (4.32–5.00)
2010 6.06 (5.53–6.72) 3,307 3.71 (3.36–4.21) 6.06 (5.53–6.72) 3.71 (3.36–4.21) 7.04 (6.40–7.82) 4.50 (4.09–5.04)
Total 1990 6.64 (6.21–7.45) 6,044 5.14 (4.77–6.17) 7.88 (7.39–8.66) 5.57 (5.19–6.51) 8.86 (8.28–9.70) 6.43 (6.02–7.27)
1995 6.76 (6.45–7.22) 6,558 5.02 (4.76–5.50) 7.85 (7.49–8.32) 5.41 (5.14–5.88) 8.88 (8.45–9.42) 6.31 (6.01–6.76)
2000 7.07 (6.83–7.36) 7,135 4.99 (4.80–5.24) 7.84 (7.57–8.15) 5.27 (5.08–5.53) 8.93 (8.61–9.30) 6.21 (5.99–6.48)
2005 7.45 (7.17–7.77) 7,715 5.02 (4.82–5.27) 7.85 (7.56–8.19) 5.16 (4.95–5.42) 9.01 (8.66–9.40) 6.13 (5.90–6.41)
2010 7.89 (7.49–8.39) 8,295 5.06 (4.80–5.47) 7.89 (7.49–8.39) 5.06 (4.79–5.47) 9.11 (8.62–9.69) 6.08 (5.76–6.50)
Data are point estimates (95% confidence intervals) of prevalence.
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We observed moderate heterogeneity among studies, particu-
larly in age categories 40 years or older (Table S2). We
therefore carried out a sensitivity analysis by repeating the
meta-analysis and meta-regression steps excluding: (i) studies
using OGTT for diabetes diagnosis31–33; and (ii) studies carried
out in a single center36,37. Analyses excluding studies using
OGTT for diabetes diagnosis (Table S3) and studies carried out
in a single center (Table S4) showed similar patterns, with a
higher diabetes prevalence in men than women and an increase
in prevalence in men aged 70 years or more with time.
Furthermore, we also examined sensitivity by including data
from the national health surveys only. This resulted in a
substantial reduction of heterogeneity and the corresponding
trends in prevalence were higher than those estimated when
using all studies (Table S5).
DISCUSSION
Here, we present the results of a comprehensive meta-regres-
sion analysis of studies carried out among the Japanese popula-
tion in the past two decades. The present study included
Table 4 | Projected age- and sex-specific diabetes prevalence (%) in the Japanese population 2010–2030
Sex Year Age category (years)
20–29 30–39 40–49 50–59 60–69 ≥70
Men 2010 0.76 (0.26–2.17) 1.71 (1.29–2.26) 5.56 (4.48–6.87) 12.00 (10.29–13.95) 17.81 (15.79–20.03) 20.13 (17.87–22.60)
2015 0.71 (0.13–3.80) 1.50 (0.99–2.25) 5.11 (3.81–6.83) 11.50 (9.26–14.19) 18.68 (15.79–21.98) 21.77 (18.41–25.53)
2020 0.67 (0.06–6.69) 1.31 (0.76–2.27) 4.71 (3.23–6.82) 11.02 (8.31–14.51) 19.59 (15.71–24.14) 23.50 (18.85–28.90)
2025 0.63 (0.03–11.53) 1.15 (0.57–2.29) 4.33 (2.71–6.84) 10.56 (7.39–14.85) 20.53 (15.63–26.52) 25.32 (19.31–32.49)
2030 0.59 (0.01–19.52) 1.01 (0.44–2.32) 3.98 (2.28–6.85) 10.12 (6.59–15.20) 21.51 (15.54–28.95) 27.23 (19.69–36.33)
Women 2010 0.59 (0.24–1.46) 0.78 (0.43–1.41) 2.40 (1.55–3.72) 5.56 (4.41–6.98) 10.65 (8.84–12.79) 12.12 (10.46–14.00)
2015 0.55 (0.14–2.17) 0.67 (0.29–1.53) 2.18 (1.20–3.94) 5.24 (3.80–7.19) 10.75 (8.28–13.82) 12.08 (9.79–14.78)
2020 0.52 (0.08–3.28) 0.57 (0.19–1.71) 1.98 (0.92–4.24) 4.93 (3.24–7.45) 10.86 (7.71–15.05) 12.03 (9.15–15.71)
2025 0.48 (0.04–5.08) 0.49 (0.12–1.91) 1.80 (0.70–4.55) 4.65 (2.76–7.72) 10.96 (7.18–16.37) 11.99 (8.48–16.68)
2030 0.45 (0.02–7.88) 0.42 (0.08–2.15) 1.64 (0.53–4.94) 4.37 (2.33–8.06) 11.06 (6.65–17.84) 11.95 (7.89–17.74)
Data are point estimates (95% confidence intervals) of prevalence.
Table 5 | Projected age-standardized diabetes prevalence in the Japanese population 2010–2030
Sex Year Standardization population
Japanese population of the
corresponding year
World population
of the corresponding
year
2010 Japanese
population
2010 world
population
2030 Japanese
population
2030 world
population
Number
of cases
(91,000)
Men 2010 9.86 (9.24–10.60) 4,988 6.43 (5.99–7.04) 9.86 (9.24–10.60) 6.43 (5.99–7.04) 11.38 (10.63–12.24) 7.67 (7.17–8.30)
2015 10.63 (9.71–11.80) 5,354 6.69 (6.09–7.73) 10.10 (9.23–11.21) 6.40 (5.82–7.45) 11.75 (10.68–13.06) 7.71 (7.05–8.74)
2020 11.41 (10.10–13.21) 5,683 7.05 (6.27–8.73) 10.36 (9.23–12.01) 6.39 (5.67–8.22) 12.16 (10.74–14.06) 7.79 (6.95–9.44)
2025 12.26 (10.51–14.87) 5,989 7.51 (6.55–10.24) 10.67 (9.25–13.03) 6.40 (5.56–9.57) 12.61 (10.82–15.25) 7.89 (6.88–10.59)
2030 13.10 (10.91–16.71) 6,228 8.02 (6.82–12.41) 11.00 (9.29–14.39) 6.44 (5.47–11.72) 13.10 (10.91–16.71) 8.02 (6.82–12.41)
Women 2010 6.06 (5.53–6.72) 3,307 3.71 (3.36–4.21) 6.06 (5.53–6.72) 3.71 (3.36–4.21) 7.04 (6.40–7.82) 4.50 (4.09–5.04)
2015 6.28 (5.52–7.29) 3,423 3.76 (3.30–4.51) 5.96 (5.25–6.92) 3.59 (3.15–4.34) 6.94 (6.07–8.07) 4.38 (3.85–5.17)
2020 6.43 (5.41–7.86) 3,478 3.85 (3.27–4.93) 5.87 (4.98–7.19) 3.49 (2.96–4.57) 6.85 (5.76–8.38) 4.28 (3.64–5.39)
2025 6.57 (5.31–8.50) 3,501 3.97 (3.27–5.48) 5.79 (4.73–7.51) 3.39 (2.78–4.94) 6.77 (5.47–8.75) 4.18 (3.44–5.71)
2030 6.69 (5.19–9.22) 3,486 4.10 (3.26–6.19) 5.72 (4.50–7.95) 3.30 (2.62–5.54) 6.69 (5.19–9.22) 4.10 (3.26–6.19)
Total 2010 7.89 (7.49–8.39) 8,295 5.06 (4.79–5.47) 7.89 (7.49–8.39) 5.06 (4.79–5.47) 9.11 (8.62–9.69) 6.08 (5.76–6.50)
2015 8.37 (7.79–9.16) 8,777 5.22 (4.86–5.88) 7.95 (7.41–8.70) 4.99 (4.64–5.65) 9.24 (8.57–10.11) 6.04 (5.64–6.71)
2020 8.81 (8.02–9.98) 9,161 5.44 (4.99–6.49) 8.03 (7.35–9.11) 4.93 (4.52–6.04) 9.38 (8.53–10.62) 6.03 (5.54–7.07)
2025 9.29 (8.26–10.94) 9,490 5.74 (5.19–7.38) 8.14 (7.30–9.65) 4.89 (4.42–6.76) 9.56 (8.50–11.23) 6.03 (5.45–7.66)
2030 9.75 (8.50–12.01) 9,714 6.05 (5.39–8.64) 8.26 (7.29–10.37) 4.86 (4.33–7.95) 9.75 (8.50–12.01) 6.05 (5.39–8.64)
Data are point estimates (95% confidence intervals) of prevalence.
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161,087 individuals, allowing us to estimate sex- and age-spe-
ciﬁc trends in the prevalence of diabetes over the past two dec-
ades, and to present prevalence projections from 2010 until
2030. Furthermore, by combining these estimates with sex- and
age-speciﬁc population distribution estimates, we also calculated
age-standardized diabetes prevalence trends as well as expected
numbers of adults with diabetes in Japan.
The present ﬁndings suggest that diabetes prevalence in
Japan will substantially increase in the next two decades, mainly
as a result of population aging. The number of cases is
expected to rise from 8.3 million in 2010 to 9.7 million in
2030. Thus, rapidly aging societies, such as Japan, Italy and
Germany1, could experience substantial increasing trends in
diabetes prevalence during the next decades. Curbing this
increase in these societies requires the identiﬁcation of effective
preventive strategies, such as promoting a healthy lifestyle and
screening for people at high risk for diabetes56. With regard to
sex- and age-speciﬁc prevalence estimates, we observed a
marked difference between men and women: prevalence is
expected to remain constant for women regardless of age cate-
gory, but to steeply increase in older men.
A major strength of the present study was its use of the stan-
dard diagnostic criteria provided in the JDS recommendation18.
This implies that the estimated trends might be attributed to
real changes in the prevalence of diabetes in the Japanese popu-
lation and not merely to changes in the criteria used to deﬁne
diabetes.
Our present estimates substantially differ from those of sev-
eral recent studies that estimated and projected diabetes preva-
lence worldwide, including the Japanese population6,11–13. The
International Diabetes Federation provided diabetes prevalence
estimates of 7.6% for 2013 and 8.2% for 203514, which are
slightly lower than those in the present study and show a less
pronounced increasing trend. This difference might be partly
explained by the fact that data used to derive the International
Diabetes Federation estimates used results from a single
national health survey carried out in 200743. Furthermore, the
International Diabetes Federation estimates are based on a
country-speciﬁc prevalence function that depends on sex, age
and level of urbanization, but does not vary with year of assess-
ment; as a result, these estimates reﬂect changes in the demo-
graphic structure of the country’s population (population
growth, aging, and urbanization), but take no account of possi-
ble trends in diabetes prevalence resulting from changes in the
inﬂuence of factors, such as unhealthy diet, sedentary lifestyle
(though this is partly taken into account through the urbaniza-
tion variable) or other possibly unexplored societal factors.
A recent article by Danaei et al.11 provided global and coun-
try-speciﬁc diabetes prevalence estimates up to 2008 using a
Bayesian hierarchical modeling procedure that included the
year of assessment as an explanatory covariate. Prevalence esti-
mates for Japan were lower than those of the present study,
but showed similar trends and differences between men and
women (4.9 and 4.2% in 1990, 7.2 and 4.7% in 2008 for men
and women respectively). However, the regression models used
to calculate these estimates were based on FPG estimates, and
the primary outcome was thus derived from studies that used
different glycemic metrics from those in our present study.
The observed sex difference in diabetes prevalence in the Jap-
anese population might be partly a result of the higher preva-
lence of obesity among Japanese men20,57,58. This sex difference
could also result from a strong inﬂuence of lifestyle habits.
Indeed, several studies have reported substantial sex differences
in alcohol and tobacco consumption, physical activity, and lev-
els of stress59,60, which could directly or indirectly inﬂuence the
development of diabetes.
The increase in diabetes prevalence along time in men aged
70 years or older might be partially explained by cohort effects;
changes in lifestyle habits between birth cohorts, particularly
changes in dietary intake since the Second World War61, might
be responsible for the trend. A possible decrease in mortality
among Japanese individuals with diabetes over time might also
explain the increasing prevalence in this age category. Alterna-
tively, because of the use of wide age categories, residual con-
founding by age might also explain the observed trend. In
contrast, we observed no evidence for such differences in diabetes
prevalence between birth cohorts in women. The reasons for this
sex difference are unclear, but the difference might possibly reﬂect
differential shifts in lifestyle habits between men and women59,60,
or the effects of sex hormones on glucose metabolism62.
The present study had several limitations. First, although the
largest studies included in our analysis covered several calendar
years, we summarized the diabetes prevalence of the corre-
sponding population for a single point in time, namely the cen-
tral year, because details about the precise year of diagnosis for
each patient were not available. As a consequence, we might
not have been able to accurately capture the temporal trend in
diabetes prevalence. In particular, results from the sensitivity
analysis using only national survey data, which did have year-
speciﬁc prevalence estimates, showed that we might have sub-
stantially underestimated the projected prevalence for both
sexes. Second, our use of wide age categories decreased the pre-
cision of our estimates of the effect of age on the prevalence of
diabetes. However, we consider that this lack of precision is
compensated for by the robustness of our estimates. Third, our
projections assume that the trends estimated by meta-regression
will remain constant during the next decades, which might not
be correct. However, given that a sudden change in the inci-
dence of diabetes is not expected, our predictions could appro-
priately describe what might happen in the absence of speciﬁc
public health policies aimed at reversing this tendency. Finally,
we observed moderate heterogeneity across studies in the prev-
alence estimates, particularly in age categories 40 years or older.
The presence of heterogeneity, while unavoidable, could have
altered the results of our meta-regression. In particular, studies
carried out in a single center might not be representative of the
overall Japanese population. The exclusion of such studies,
however, did not materially change prevalence estimates. Fur-
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thermore, the restriction of the analysis to data from the
national health surveys, which have a very similar design and
consequently exhibit much less heterogeneity, showed higher
trends in prevalence. However, because participants in the
national health surveys tend to be more cooperative and per-
haps more health-conscious than the average, despite the ran-
dom selection procedure used at the time of recruitment, these
surveys might fail to encompass the Japanese population in all
its diversity. For that reason, we believe that the estimates pre-
sented, based on all the studies included, might give a better
reﬂection of the trends in diabetes prevalence in the Japanese
population.
In conclusion, this comprehensive meta-regression analysis of
the Japanese population shows that diabetes can be expected to
substantially increase in the next few decades, and that this
increase will be mainly a result of population aging. Because
diabetes is preventable through diet and lifestyle modiﬁcation,
our ﬁndings support the need for public policies and health
systems that promote a healthy diet and lifestyle.
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